Technology
Upcoming Earnings
Health

Merus

$16.81
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.62 (3.83%) Today
-$0.01 (-0.06%) As of 4:00 PM EDT after-hours

Why Robinhood?

You can buy or sell Merus and other stocks, options, ETFs, and crypto commission-free!

About MRUS

Merus N.V. Common Shares, also called Merus, is a clinical-stage immune-oncology company, which engages in the discovery and development of bi-specific antibody therapeutics. Read More Its pipeline includes Biclonics for solid and hematological tumors. The company was founded by Ton Logtenberg on June 16, 2003 and is headquartered in Utrecht, Netherlands.

Employees
98,000
Headquarters
Utrecht, Utrecht
Founded
2003
Market Cap
393.25M
Price-Earnings Ratio
Dividend Yield
Average Volume
52.31K
High Today
$17.63
Low Today
$16.24
Open Price
$16.25
Volume
74.68K
52 Week High
$22.46
52 Week Low
$11.00

Collections

Technology
Upcoming Earnings
Health
Biotechnology
Medical
Therapy
2016 IPO
Europe (Non-UK)

MRUS Earnings

-$0.89
-$0.60
-$0.31
-$0.02
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
-$0.53 per share
Actual
Expected Aug 17, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.